Improving the identification of retinal biomarkers of Alzheimer disease in vivo

提高阿尔茨海默病视网膜生物标志物的体内鉴定

• 批准号: 523599-2018
• 负责人: Lesage, Frederic
• 金额: $ 5.63万
• 依托单位: École Polytechnique de Montréal
• 依托单位国家: 加拿大
• 项目类别: Collaborative Health Research Projects
• 财政年份: 2018
• 资助国家: 加拿大
• 起止时间: 2018-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=657256
• 关键词: Improving; identification; retinal; biomarkers; Alzheimer

Alzheimers disease is a slowly evolving neurodegenerative disorder that ultimately leading to**dementia. It is the most common cause of dementia, affecting millions worldwide, with no cure**available at this time. One of the main issues with developing new therapies is the fact that**Alzheimer is usually diagnosed based on cognitive impairments, a diagnosis made late in the**evolution of the disease. This proposal aims to develop a non-invasive detection tool**exploiting commonalities between Alzheimer biomarkers present both in the brain and the**eye. Our main goal is to identify signs of the disease earlier using a test that could be done**routinely during an ophthalmology examination. We will develop methods combining**multispectral retinal imaging with image processing to identify biomarkers of amyloid plaque**accumulation in the retina and correlate results with brain PET amyloid imaging.

阿尔茨海默病是一种缓慢演变的神经退行性疾病，最终会导致**痴呆症。它是痴呆症最常见的原因，影响着全世界数百万人，目前还没有治愈方法。开发新疗法的主要问题之一是，阿尔茨海默氏症的诊断通常是基于认知障碍，这一诊断是在疾病进化的后期做出的。这项提议旨在开发一种非侵入性检测工具，**利用大脑和眼睛中存在的阿尔茨海默病生物标记物之间的共性。我们的主要目标是使用一种可以在眼科检查期间常规进行的测试来更早地识别疾病的迹象。我们将开发将**多光谱视网膜成像与图像处理相结合的方法，以识别视网膜中积累的淀粉样斑块**的生物标记物，并将结果与脑PET淀粉样成像相关联。